Guillaume Lereaux

Guillaume Lereaux

Auto-generated profile, based on publicly available information

Guillaume Lereaux

L'Oréal Research and Innovation Aulnay France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
PSPeggy Sextius
Peggy Sextius
EWEmilie Warrick
Emilie Warrick
APAmélie Prévot‐Guéguiniat
Amélie Prévot‐Guéguiniat
GLGuillaume Lereaux
Guillaume Lereaux
FBFlorence Boirre
Florence Boirre
XMXavier Marat
Xavier Marat
Research on new ingredients that can prevent excessive melanin production in the skin while considering efficacy, safety but also environmental impact is of great importance to significantly improve the profile of existing actives on the market and avoid undesirable side effects. Here, the discovery of an innovative technology for the management of hyperpigmentation is described. High‐throughput screening tests on a wide chemical diversity of molecules and in silico predictive methodologies were essential to design an original thiopyridinone backbone and select 2‐mercaptonicotinoyl glycine (2‐MNG) as exhibiting the most favorable balance between the impact on water footprint, skin penetration potential and performance. The effectiveness of 2‐MNG was confirmed by topical application on pigmented reconstructed epidermis and human skin explants. In addition, experiments have shown that unlike most melanogenesis inhibitors on the market, this molecule is not a tyrosinase inhibitor. 2‐MNG binds to certain melanin precursors, preventing their integration into growing melanin and leading to inhibition of eumelanin and pheomelanin synthesis, without compromising the integrity of melanocytes.